Marshall J S, Green A M, Pensky J, Williams S, Zinn A, Carlson D M
J Clin Invest. 1974 Sep;54(3):555-62. doi: 10.1172/JCI107792.
Addition of increasing amounts of (125)I-labeled desialylated thyroxine-binding globulin (DTBG) to hepatic cell membranes resulted in a progressive increase in binding. Saturability of membrane sites was indicated by a concentration beyond which further increases in [(125)I]DTBG resulted in no further binding. The binding curve for [(125)I]DTBG was similar to binding curves of desialylated orosomucoid, fetuin, and ceruloplasmin. An inhibition assay system using hepatic cell membranes showed that desialylated orosomucoid had a greater affinity for membrane binding sites than did DTBG but desialylated fetuin and ceruloplasmin bound less avidly than DTBG. Serum from normal persons and patients with a variety of illnesses was tested for its ability to inhibit [(125)I]DTBG binding. The inhibitory activity of 1 ml of normal serum was equivalent to that of 0.2-2 mug DTBG. Patients with Laënnec's cirrhosis, biliary cirrhosis, and hepatic metastases had greatly increased inhibitory activity in their serum. Patients with jaundice due to extrahepatic obstruction had inhibitory activity not significantly different from that found in normal serum. Column chromatography of normal serum on Sephadex G-200 resulted in inhibitory activity throughout the range of protein molecular weight. Desialylation of normal serum with neuraminidase enhanced the inhibitory activity but did not change the distribution of the activity. Gel chromatography of cirrhotic serum showed markedly increased inhibitory activity associated with the macroglobulins and the 4.5S peak and a new peak of inhibitory activity in the low molecular weight area was also seen. Inhibition of desialylated glycoprotein binding to liver cell membranes by serum from patients with hepatocellular disease raises the possibility that desialylated serum glycoproteins accumulate in the circulation and that patients with compromised hepatocellular function may no longer be able to clear them from the circulation. Alternatively, accumulation of desialylated glycoproteins in the circulation could result from defective protein synthesis by the diseased liver.
向肝细胞膜中添加越来越多的(125)I标记的去唾液酸甲状腺素结合球蛋白(DTBG)会导致结合量逐渐增加。当达到一定浓度后,膜位点达到饱和,此时再增加[(125)I]DTBG的量不会导致进一步的结合,这表明了膜位点的饱和性。[(125)I]DTBG的结合曲线与去唾液酸类粘蛋白、胎球蛋白和铜蓝蛋白的结合曲线相似。使用肝细胞膜的抑制试验系统表明,去唾液酸类粘蛋白对膜结合位点的亲和力比DTBG大,但去唾液酸胎球蛋白和铜蓝蛋白的结合不如DTBG强烈。检测了正常人和患有各种疾病患者的血清抑制[(125)I]DTBG结合的能力。1ml正常血清的抑制活性相当于0.2 - 2μg DTBG的抑制活性。Laënnec肝硬化、胆汁性肝硬化和肝转移患者的血清中抑制活性大大增加。肝外梗阻性黄疸患者的抑制活性与正常血清中的抑制活性无显著差异。正常血清在Sephadex G - 200上进行柱层析,在整个蛋白质分子量范围内都有抑制活性。用神经氨酸酶对正常血清进行去唾液酸化增强了抑制活性,但没有改变活性的分布。肝硬化血清的凝胶层析显示,与巨球蛋白和4.5S峰相关的抑制活性明显增加,并且在低分子量区域也出现了一个新的抑制活性峰。肝细胞疾病患者血清对去唾液酸糖蛋白与肝细胞膜结合的抑制作用增加了这样一种可能性,即去唾液酸血清糖蛋白在循环中积累,并且肝细胞功能受损的患者可能不再能够从循环中清除它们。或者,循环中去唾液酸糖蛋白的积累可能是由于患病肝脏蛋白质合成缺陷所致。